A Ketogenic Diet Program With KetoCitra for Polycystic Kidney Disease
Tests a nutritionist-led ketogenic diet plus KetoCitra in adults with polycystic kidney disease.
Plain-language title generated from the registry record
Registry title: Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease
Key facts
- Where
- Cleveland, United StatesSee the site
Where in United States
- Cleveland ClinicCleveland, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Richard Fatica
- Trial code
- NCT07454174
- Record updated
- 6 March 2026
- Original description
This is a 16 week pilot study of the impact of a nutritionist led ketogenic diet (Ren-Nu) supplemented with the medical food KetoCitra on autosomal dominant polycystic kidney disease.Read full original descriptionShow less
Short-Term Metabolic Impacts of Ren-Nu: A Dietary Program for Individuals With Polycystic Kidney Disease
This is a 16 week pilot study of the impact of a nutritionist led ketogenic diet (Ren-Nu) supplemented with the medical food KetoCitra on autosomal dominant polycystic kidney disease.
Inclusion: Adult (18 years or older); Diagnosis of ADPKD by a physician; Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2 at screening using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; Appropriate control of blood pressure (i.e. entry reading <140/90) including the use of BP medications for diagnosis of hypertension; BMI ≥ 25 (accounting for muscle mass); Own an at-home blood pressure monitor (no brand requirements); Able to complete study-related activities (e.g., attend online classes, complete questionnaires, and proper use of medical devices).
Exclusion: Intolerance or allergy to any of the ingredients in the provided medical food; Severe or rare underlying health conditions may cause a safety risk when taking the medical food. Those underlying health conditions will be assessed by the enrolling physician and include but are not limited to:; History of hyperkalemia; Heart failure; Liver cirrhosis; Chronic kidney disease stage 4 or greater, or other renal condition that severely impairs bone mineral homeostasis; HIV infection; Chronic drug or alcohol abuse; Chronic malabsorption syndrome; Malignancy (non-melanoma skin cancer exempted); Autoimmune disease; Pregnant, planning to be pregnant, or nursing during the course of the study; Chronic history of recurrent urinary tract infections (UTI) (≥ 3 UTIs per year); Diagnosis of aneurysm; Indigestion due to hypochlorhydria (low stomach acid); Any other condition, that in the opinion of the enrolling physician, makes the subject an unsuitable candidate for the study; Current use of any of the following medications or supplements which could affect safety or compliance with this study:; The medical food, KetoCitra®; Urine alkalizing agents such as sodium bicarbonate or potassium citrate; Citrate treatments; Immunosuppressive treatment; Tolvaptan; Potassium-sparing diuretics; Somatostatin analogs; Aluminum-containing supplements or medications such as aluminum antacids (e.g. Maalox) or aluminum-based phosphate binders; SGLT2 inhibitors; Participation in another therapeutic intervention trial; Following a highly specialized or extreme diet that is incompatible with the interventional nutrition program (e.g. carnivore, very high protein diet for elite athletes, etc.); Food sensitivities or allergies that are incompatible with the interventional nutrition program; The subject is already adhering to a form of a ketogenic diet or related fasting regimen; Current or past history of disordered eating or feeding behaviors; History of gastric bypass; Active diagnosis of ulcerative colitis, Irritable Bowel Syndrome, Crohn's, or Gallbladder Disease.